Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.

Autor: Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: tsimuni@nm.org., Chahine LM; Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA., Poston K; Department of Neurology, Stanford University School of Medicine, Palo Alto, CA, USA., Brumm M; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA., Buracchio T; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA., Campbell M; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA., Chowdhury S; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Coffey C; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA., Concha-Marambio L; Amprion, San Diego, CA, USA., Dam T; Biogen, Cambridge, MA, USA., DiBiaso P; Patient Advisory Council, New York, NY, USA; Clinical Solutions and Strategic Partnerships, WCG Clinical, Princeton, NJ, USA., Foroud T; Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA., Frasier M; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Gochanour C; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA., Jennings D; Denali Therapeutics, San Francisco, CA, USA., Kieburtz K; Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA., Kopil CM; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Merchant K; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Mollenhauer B; Department of Neurology, University Medical Center Göttingen and Paracelsus-Elena-Klinik, Kassel, Germany., Montine T; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Nudelman K; Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA., Pagano G; F Hoffmann-La Roche, Basel, Switzerland., Seibyl J; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Sherer T; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Singleton A; National Institute on Aging, National Institutes of Health, Bethesda, MD, USA., Stephenson D; Critical Path for Parkinson's, Critical Path Institute, Tucson, AZ, USA., Stern M; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Soto C; Amprion, San Diego, CA, USA; Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas McGovern Medical School at Houston, Houston, TX, USA., Tanner CM; Movement Disorders and Neuromodulation Center, Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, CA, USA; Parkinson's Disease Research Education and Clinical Center, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA., Tolosa E; Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain., Weintraub D; University of Pennsylvania and the Parkinson's Disease and Mental Illness Research, Education and Clinical Centers, Philadelphia Veterans Affairs Medical Center Philadelphia, PA, USA., Xiao Y; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Siderowf A; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Dunn B; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA.

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2024 Feb; Vol. 23 (2), pp. 178-190.

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

Autor: Simuni, T, Merchant, K, Brumm, MC, Cho, H, Caspell-Garcia, C, Coffey, CS, Chahine, LM, Alcalay, RN, Nudelman, K, Foroud, T, Mollenhauer, B, Siderowf, A, Tanner, C, Iwaki, H, Sherer, T, Marek, K, Seibyl, J, Coffey, C, Tosun-Turgut, D, Shaw, LM, Trojanowski, JQ, Singleton, A, Kieburtz, K, Toga, A, Galasko, D, Poewe, W, Poston, K, Bressman, S, Reimer, A, Arnedo, V, Clark, A, Frasier, M, Kopil, C, Chowdhury, S, Casaceli, C, Dorsey, R, Wilson, R, Mahes, S, Salerno, C, Ahrens, M, Brumm, M, Cho, HR, Fedler, J, LaFontant, D-E, Kurth, R, Crawford, K, Casalin, P, Malferrari, G, Weisz, MG, Orr-Urtreger, A, Trojanowski, J, Shaw, L, Montine, T, Baglieri, C, Christini, A, Russell, D, Dahodwala, N, Giladi, N, Factor, S, Hogarth, P, Standaert, D, Hauser, R, Jankovic, J, Saint-Hilaire, M, Richard, I, Shprecher, D, Fernandez, H, Brockmann, K, Rosenthal, L, Barone, P, Espayc, A, Rowe, D, Marder, K, Santiago, A, Hu, S-C, Isaacson, S, Corvol, J-C, Martinez, JR, Tolosa, E, Tai, Y, Politis, M, Smejdir, D, Rees, L, Williams, K, Kausar, F, Richardson, W, Willeke, D, Peacock, S, Sommerfeld, B, Freed, A, Wakeman, K, Blair, C, Guthrie, S, Harrell, L, Hunter, C, Thomas, C-A, James, R, Zimmerman, G, Brown, V, Mule, J, Hilt, E, Ribb, K, Ainscough, S, Wethington, M, Ranola, M, Santana, HM, Moreno, J, Raymond, D, Speketer, K, Carvajal, L, Carvalo, S, Croitoru, I, Garrido, A, Payne, LM, Viswanth, V, Severt, L, Facheris, M, Soares, H, Mintun, MA, Cedarbaum, J, Taylor, P, Biglan, K, Vandenbroucke, E, Sheikh, ZH, Bingol, B, Fischer, T, Sardi, P, Forrat, R, Reith, A, Egebjerg, J, Hillert, GA, Saba, B, Min, C, Umek, R, Mather, J, De Santi, S, Post, A, Boess, F, Taylor, K, Grachev, I, Avbersek, A, Muglia, P, Tauscher, J

We examined 2-year longitudinal change in clinical features and biomarkers in LRRK2 non-manifesting carriers (NMCs) versus healthy controls (HCs) enrolled in the Parkinson’s Progression Markers Initiative (PPMI). We analyzed 2-year longitudinal dat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::57cb78cbdcff5c5771194646efb11352
http://hdl.handle.net/10044/1/101202

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts.

Autor: Merchant KM; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. kalpana.merchant@northwestern.edu., Simuni T; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Fedler J; The University of Iowa, Iowa City, IA, USA., Caspell-Garcia C; The University of Iowa, Iowa City, IA, USA., Brumm M; The University of Iowa, Iowa City, IA, USA., Nudelman KNH; Indiana University School of Medicine, Indianapolis, IN, USA., Tengstrandt E; Nextcea, Inc, Woburn, MA, USA., Hsieh F; Nextcea, Inc, Woburn, MA, USA., Alcalay RN; Columbia University, New York, NY, USA., Coffey C; The University of Iowa, Iowa City, IA, USA., Chahine L; University of Pittsburg, Pittsburgh, PA, USA., Foroud T; Indiana University, Indianapolis, IN, USA., Singleton A; National Institute on Aging, NIH, Bethesda, MD, USA., Weintraub D; The University of Pennsylvania, Philadelphia, PA, USA., Hutten S; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Sherer T; The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA., Mollenhauer B; University Medical Center Goettingen, Parcacelsus Kliniken Germany, Göttingen, Germany., Siderowf A; The University of Pennsylvania, Philadelphia, PA, USA., Tanner C; University of California San Francisco, San Francisco, CA, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA.

Publikováno v: NPJ Parkinson's disease [NPJ Parkinsons Dis] 2023 Feb 28; Vol. 9 (1), pp. 30. Date of Electronic Publication: 2023 Feb 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.